Ionis Pharmaceuticals (IONS) Research & Development (2009 - 2026)

Ionis Pharmaceuticals' Research & Development history runs 18 years deep, the most recent figure standing at $217.1 million for Q2 2026.

• In Q2 2026, Research & Development changed 0.16% year-over-year to $217.1 million; the TTM figure through Jun 2026 stood at $924.7 million (up 4.66% YoY), while the FY2025 annual figure was $915.6 million, up 1.56% from the prior year.
• Research & Development for Q2 2026 stood at $217.1 million, up from $210.2 million in the prior quarter.
• The five-year high for Research & Development was $279.6 million in Q4 2025, with the low at -$444.9 million in Q4 2022.
• The 5-year median for Research & Development is $216.2 million (2023), against an average of $179.1 million.
• The sharpest annual moves came in 2023 and 2025: Research & Development soared 157.67% in 2023, then fell 6.28% in 2025.
• Ionis Pharmaceuticals' Research & Development stood at -$444.9 million in 2022, then jumped by 157.67% to $256.6 million in 2023, then slipped by 4.31% to $245.5 million in 2024, then increased by 13.91% to $279.6 million in 2025, then dropped by 22.36% to $217.1 million in 2026.
• Business Quant data shows IONS's Research & Development at $217.1 million in Q2 2026, $210.2 million in Q1 2026, and $279.6 million in Q4 2025.